Nemes Rush Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.56M Buy
25,698
+130
+0.5% +$7.58K 0.15% 86
2025
Q4
$1.38M Sell
25,568
-1,241
-5% -$59.7K 0.13% 90
2025
Q3
$1.21M Buy
26,809
+76
+0.3% +$3.55K 0.12% 89
2025
Q2
$1.24M Sell
26,733
-294
-1% -$14.4K 0.13% 91
2025
Q1
$1.65M Hold
27,027
0.21% 70
2024
Q4
$1.53M Buy
27,027
+221
+0.8% +$12.3K 0.19% 70
2024
Q3
$1.45M Sell
26,806
-18
-0.1% -$844 0.21% 73
2024
Q2
$1.11M Buy
26,824
+18
+0.1% +$805 0.15% 81
2024
Q1
$1.45M Buy
26,806
+31
+0.1% +$1.58K 0.21% 73
2023
Q4
$1.37M Sell
26,775
-702
-3% -$36.8K 0.22% 75
2023
Q3
$1.59M Sell
27,477
-2,491
-8% -$153K 0.29% 70
2023
Q2
$1.92M Buy
+29,968
New +$2.01M 0.34% 61

Other funds holding BMY

Nemes Rush Group's BMY Position: Q1 2026 in Review

Nemes Rush Group increased its Bristol-Myers Squibb (BMY) stake by 0.51% in Q1 2026, buying an estimated $7.58K and bringing the position to 25,698 shares worth $1.56M. The position accounts for 0.15% of the portfolio, ranked #86.

Nemes Rush Group first reported a position in BMY in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.92M in Q2 2023. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Nemes Rush Group held 25,698 shares of Bristol-Myers Squibb worth $1.56M as of Q1 2026.
  • Nemes Rush Group bought 130 Bristol-Myers Squibb shares in Q1 2026, an estimated $7.58K.
  • Bristol-Myers Squibb made up 0.15% of Nemes Rush Group's portfolio in Q1 2026, its #86 holding.
  • Nemes Rush Group first reported a position in Bristol-Myers Squibb in Q2 2023 and has held it in 12 quarters since.
  • Nemes Rush Group's Bristol-Myers Squibb position peaked at $1.92M in Q2 2023.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.